BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Philosys Awarded CE Mark for New Gmate® SMART Meter and Seeks Global Telecommunications Partners


8/14/2012 7:35:29 AM

NEW YORK, Aug. 13, 2012 /PRNewswire/ -- Philosys announced today that it has received the CE Mark for the Gmate® SMART Blood Glucose Monitoring System. According to Jonathan Johnson, Director of Regulatory Affairs, "CE designation will allow Philosys to market the Gmate® SMART within the European Union,(EU), consisting of the 27 EU Member States. Moreover, the CE mark signifies that the product has been assessed before being placed on the market and meets European Union safety, health and environmental protection requirements." Gmate® SMART is the first of its kind blood glucose monitor to work with the iPhone, iPad and iPod devices. The CE Mark approval is an important milestone for Philosys in offering innovative technology to diabetics around the globe. Planning for the European market has been underway for more than a year and diabetic patients in the EU should be able to begin using the Gmate® SMART before the end of 2012.

"With the launch of the Gmate® SMART in Europe, Philosys provides the perfect solution to diabetics looking for new technology to help monitor blood glucose levels in an active, fast paced lifestyle," said Jennifer Kupar, Manager of Operations at Philosys. "As smart phone usage continues to increase in Europe, there is a growing demand for this breakthrough patent-pending technology that Philosys can deliver," Kupar continued.

As a next step, Philosys is pursuing global telecommunications contracts for the Gmate® SMART. Philosys is seeking to partner with major cell phone providers in a variety of markets to provide innovative health solutions to diabetic patients and health systems.

About Gmate
The Gmate® SMART is the smallest, most innovative glucose meter in the world. The patent pending technology of the Gmate® SMART uses the operating system of the smart phone and works by plugging the device into the headphone connector of the smart phone, and launching the companion app.

For more information please visit www.gmate.com or contact Jennifer Kupar at jkupar@gmate.com

SOURCE Philosys, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES